Topical application of the hematostatic agent Surgiflo® could attenuate brain injury in experimental TBI mice

Dewei Guo, Dongpeng Li, Jinghong Li, Yunfeng Li, Xiang Hu, Fangxia Guan, Bo Yang

Research output: Contribution to journalArticle

Abstract

Object: The pathologies resulting from traumatic brain injury (TBI) have been thoroughly studied, but rarely have the effects of bleeding and coagulation in the early stage of TBI been considered. In this study, we investigated the effects of topical Surgiflo® application on brain injury in experimental TBI mice using S100β, MAP-2 and mNSS scores. Methods: TBI was induced by modified weight drop injury in male C57BL/6 mice. The mice were then randomly divided into (i) the sham group, (ii) TBI mice applied with saline (vehicle), and (iii) TBI mice applied with Surgiflo® in the same volume. Modified neurological severity scores (mNSS) were measured on days 0 (before surgery), 1, 3, 7, and 28 to evaluate neurologic functional deficits. At day 28, the mice were sacrificed, and the forebrains were sliced. The effects of Surgiflo® on microtubule-associated protein 2 and serum S100β protein were examined by immunohistochemistry and electro-chemiluminescence immunoassay. Results: Serum S100β protein levels were significantly elevated at different time points (24 h, 3 days, 7 days) in the TBI groups (p  <  0.01) compared to normal control groups. Surgiflo® induced a lower concentration of serum S100β protein levels at day 3 (p < 0.05) and day 7 (p < 0.05) compared to the TBI group applied with saline. H&E staining showed that Surgiflo® treatment led to a 45% decrease in cortical brain lesion volume and in subcortical white matter 28 days after TBI. Compared with the saline-treated group, the number of MAP2-positive cells was significantly increased in the perilesional area of the Surgiflo®-treated group. The Surgiflo®-treated group exhibited lower mNSS scores on days 7 and 28 than did the saline-treated group. Discussion: Surgiflo® treatment produced a significant decrease in serum S100β protein levels in TBI mouse models, which may lead to an improvement in the recovery of TBI models.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalNeurological Research
DOIs
StateAccepted/In press - Jun 1 2017
Externally publishedYes

Fingerprint

Brain Injuries
S100 Proteins
Blood Proteins
Traumatic Brain Injury
Microtubule-Associated Proteins
Prosencephalon
Neurologic Manifestations
Luminescence
Inbred C57BL Mouse
Immunoassay
Immunohistochemistry
Pathology
Staining and Labeling
Hemorrhage
Weights and Measures
Control Groups
Wounds and Injuries
Brain
Therapeutics

Keywords

  • haemostat
  • neuroprotection
  • S100β
  • Surgiflo
  • Traumatic brain injury

ASJC Scopus subject areas

  • Medicine(all)
  • Neurology
  • Clinical Neurology

Cite this

Topical application of the hematostatic agent Surgiflo® could attenuate brain injury in experimental TBI mice. / Guo, Dewei; Li, Dongpeng; Li, Jinghong; Li, Yunfeng; Hu, Xiang; Guan, Fangxia; Yang, Bo.

In: Neurological Research, 01.06.2017, p. 1-7.

Research output: Contribution to journalArticle

Guo, Dewei ; Li, Dongpeng ; Li, Jinghong ; Li, Yunfeng ; Hu, Xiang ; Guan, Fangxia ; Yang, Bo. / Topical application of the hematostatic agent Surgiflo® could attenuate brain injury in experimental TBI mice. In: Neurological Research. 2017 ; pp. 1-7.
@article{306431ac4eff43a881057835df676d50,
title = "Topical application of the hematostatic agent Surgiflo{\circledR} could attenuate brain injury in experimental TBI mice",
abstract = "Object: The pathologies resulting from traumatic brain injury (TBI) have been thoroughly studied, but rarely have the effects of bleeding and coagulation in the early stage of TBI been considered. In this study, we investigated the effects of topical Surgiflo{\circledR} application on brain injury in experimental TBI mice using S100β, MAP-2 and mNSS scores. Methods: TBI was induced by modified weight drop injury in male C57BL/6 mice. The mice were then randomly divided into (i) the sham group, (ii) TBI mice applied with saline (vehicle), and (iii) TBI mice applied with Surgiflo{\circledR} in the same volume. Modified neurological severity scores (mNSS) were measured on days 0 (before surgery), 1, 3, 7, and 28 to evaluate neurologic functional deficits. At day 28, the mice were sacrificed, and the forebrains were sliced. The effects of Surgiflo{\circledR} on microtubule-associated protein 2 and serum S100β protein were examined by immunohistochemistry and electro-chemiluminescence immunoassay. Results: Serum S100β protein levels were significantly elevated at different time points (24 h, 3 days, 7 days) in the TBI groups (p  <  0.01) compared to normal control groups. Surgiflo{\circledR} induced a lower concentration of serum S100β protein levels at day 3 (p < 0.05) and day 7 (p < 0.05) compared to the TBI group applied with saline. H&E staining showed that Surgiflo{\circledR} treatment led to a 45{\%} decrease in cortical brain lesion volume and in subcortical white matter 28 days after TBI. Compared with the saline-treated group, the number of MAP2-positive cells was significantly increased in the perilesional area of the Surgiflo{\circledR}-treated group. The Surgiflo{\circledR}-treated group exhibited lower mNSS scores on days 7 and 28 than did the saline-treated group. Discussion: Surgiflo{\circledR} treatment produced a significant decrease in serum S100β protein levels in TBI mouse models, which may lead to an improvement in the recovery of TBI models.",
keywords = "haemostat, neuroprotection, S100β, Surgiflo, Traumatic brain injury",
author = "Dewei Guo and Dongpeng Li and Jinghong Li and Yunfeng Li and Xiang Hu and Fangxia Guan and Bo Yang",
year = "2017",
month = "6",
day = "1",
doi = "10.1080/01616412.2017.1330815",
language = "English (US)",
pages = "1--7",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",

}

TY - JOUR

T1 - Topical application of the hematostatic agent Surgiflo® could attenuate brain injury in experimental TBI mice

AU - Guo, Dewei

AU - Li, Dongpeng

AU - Li, Jinghong

AU - Li, Yunfeng

AU - Hu, Xiang

AU - Guan, Fangxia

AU - Yang, Bo

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Object: The pathologies resulting from traumatic brain injury (TBI) have been thoroughly studied, but rarely have the effects of bleeding and coagulation in the early stage of TBI been considered. In this study, we investigated the effects of topical Surgiflo® application on brain injury in experimental TBI mice using S100β, MAP-2 and mNSS scores. Methods: TBI was induced by modified weight drop injury in male C57BL/6 mice. The mice were then randomly divided into (i) the sham group, (ii) TBI mice applied with saline (vehicle), and (iii) TBI mice applied with Surgiflo® in the same volume. Modified neurological severity scores (mNSS) were measured on days 0 (before surgery), 1, 3, 7, and 28 to evaluate neurologic functional deficits. At day 28, the mice were sacrificed, and the forebrains were sliced. The effects of Surgiflo® on microtubule-associated protein 2 and serum S100β protein were examined by immunohistochemistry and electro-chemiluminescence immunoassay. Results: Serum S100β protein levels were significantly elevated at different time points (24 h, 3 days, 7 days) in the TBI groups (p  <  0.01) compared to normal control groups. Surgiflo® induced a lower concentration of serum S100β protein levels at day 3 (p < 0.05) and day 7 (p < 0.05) compared to the TBI group applied with saline. H&E staining showed that Surgiflo® treatment led to a 45% decrease in cortical brain lesion volume and in subcortical white matter 28 days after TBI. Compared with the saline-treated group, the number of MAP2-positive cells was significantly increased in the perilesional area of the Surgiflo®-treated group. The Surgiflo®-treated group exhibited lower mNSS scores on days 7 and 28 than did the saline-treated group. Discussion: Surgiflo® treatment produced a significant decrease in serum S100β protein levels in TBI mouse models, which may lead to an improvement in the recovery of TBI models.

AB - Object: The pathologies resulting from traumatic brain injury (TBI) have been thoroughly studied, but rarely have the effects of bleeding and coagulation in the early stage of TBI been considered. In this study, we investigated the effects of topical Surgiflo® application on brain injury in experimental TBI mice using S100β, MAP-2 and mNSS scores. Methods: TBI was induced by modified weight drop injury in male C57BL/6 mice. The mice were then randomly divided into (i) the sham group, (ii) TBI mice applied with saline (vehicle), and (iii) TBI mice applied with Surgiflo® in the same volume. Modified neurological severity scores (mNSS) were measured on days 0 (before surgery), 1, 3, 7, and 28 to evaluate neurologic functional deficits. At day 28, the mice were sacrificed, and the forebrains were sliced. The effects of Surgiflo® on microtubule-associated protein 2 and serum S100β protein were examined by immunohistochemistry and electro-chemiluminescence immunoassay. Results: Serum S100β protein levels were significantly elevated at different time points (24 h, 3 days, 7 days) in the TBI groups (p  <  0.01) compared to normal control groups. Surgiflo® induced a lower concentration of serum S100β protein levels at day 3 (p < 0.05) and day 7 (p < 0.05) compared to the TBI group applied with saline. H&E staining showed that Surgiflo® treatment led to a 45% decrease in cortical brain lesion volume and in subcortical white matter 28 days after TBI. Compared with the saline-treated group, the number of MAP2-positive cells was significantly increased in the perilesional area of the Surgiflo®-treated group. The Surgiflo®-treated group exhibited lower mNSS scores on days 7 and 28 than did the saline-treated group. Discussion: Surgiflo® treatment produced a significant decrease in serum S100β protein levels in TBI mouse models, which may lead to an improvement in the recovery of TBI models.

KW - haemostat

KW - neuroprotection

KW - S100β

KW - Surgiflo

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85020225686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020225686&partnerID=8YFLogxK

U2 - 10.1080/01616412.2017.1330815

DO - 10.1080/01616412.2017.1330815

M3 - Article

C2 - 28566060

AN - SCOPUS:85020225686

SP - 1

EP - 7

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

ER -